Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday&#39

Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX s

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or

Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq

Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared prel

Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than contro

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ

Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi

Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transpl

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

- Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasd

The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRAC

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or t

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the anal

Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patie

Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from

Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rate

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~

The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposur

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseH

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an

This milestone triggers the final phase of preparation for the trial's interim 45 subject data u

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the ana

Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc